Cover ImageSALE
Market Research Report

Global Chronic Lymphocytic Leukemia market 2016-2020

Published by TechNavio (Infiniti Research Ltd.) Product code 359355
Published Content info 78 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Chronic Lymphocytic Leukemia market 2016-2020
Published: June 1, 2016 Content info: 78 Pages
Description

About the Chronic Lymphocytic Leukemia (CLL) Therapeutics Market

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:

  • Acute myeloid (or myelogenous) leukemia (AML)
  • Chronic myeloid (or myelogenous) leukemia (CML)
  • Acute lymphocytic (or lymphoblastic) leukemia (ALL)
  • CLL

Technavio's analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hoffman-La Roche
  • AbbVie
  • Teva Pharmaceuticals
  • Gilead Sciences
  • Novartis
  • Johnson & Johnson

Other Prominent Vendors

  • Altor BioScience
  • Amgen
  • Arno Therapeutics
  • AstraZeneca
  • Bellicum Pharmaceuticals
  • Biogen
  • BioLineRx
  • Boston Biomedical
  • Celgene
  • Emergent BioSolutions
  • Genzyme
  • iDD biotech
  • Immunomedics
  • Infinity Pharmaceuticals
  • Innate Pharma
  • Karyopharm Therapeutics
  • Ligand Pharmaceuticals
  • MedImmune
  • Merck Sharp & Dohme
  • Molecular Templates Inc.
  • MorphoSys
  • Ono Pharmaceutical
  • Portola Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Sunesis Pharmaceuticals
  • TG Therapeutics
  • TheraMAB
  • XEME Biopharma
  • Xencor
  • ZIOPHARM Oncology

Market driver

  • Special regulatory designations
  • For a full, detailed list, view our report

Market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Market trend

  • Rise in development of combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents
Product Code: IRTNTR9378

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Types of CLL
  • Symptoms
  • Diagnosis
  • Staging
  • Management
  • Key buying criteria

PART 06: Pipeline analysis

  • Acalabrutinib
  • TG-1101 + ibrutinib
  • TGR-1202
  • Venetoclax + obinutuzumab
  • Venetoclax + rituximab
  • REVLIMID
  • Duvelisib

PART 07: Market landscape

  • Global CLL therapeutics market
  • Total addressable market for global CLL therapeutics
  • Five forces analysis

PART 08: Market segmentation by ROA

  • Oral
  • Parenteral

PART 09: Market segmentation by type of molecule

  • Small molecules
  • Biologics

PART 10: Geographical segmentation

  • Global CLL therapeutics market by geographical segmentation 2015-2020
  • CLL therapeutics market in Americas
  • CLL therapeutics market in EMEA
  • CLL therapeutics market in APAC

PART 11: Market drivers

  • Special regulatory designations
  • Recent drug approvals
  • Application for expanded indication approvals
  • Increase in patient pool

PART 12: Impact of drivers

PART 13: Market challenges

  • High cost of therapy
  • Availability of chemotherapy and off-label drugs
  • Adverse effects of drugs
  • Stringent regulatory guidelines

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Joint ventures and partnerships
  • Patient assistance programs
  • Rise in development of combination therapies
  • Growing public awareness
  • PART 16: Vendor landscape
  • Competitive scenario
  • Market share analysis 2015
  • F. Hoffmann-La Roche
  • AbbVie
  • Teva Pharmaceuticals
  • Johnson & Johnson
  • Gilead Sciences
  • Novartis
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Timeline of development of leukemia drugs
  • Exhibit 03: Snapshot of CLL
  • Exhibit 04: Types of CLL
  • Exhibit 05: Main diagnostic procedures to determine presence of CLL
  • Exhibit 06: Other diagnostic procedures to determine presence of CLL
  • Exhibit 07: Rai stages of CLL
  • Exhibit 08: Binet stages of CLL
  • Exhibit 09: Management of CLL
  • Exhibit 10: Key buying criteria for CLL drugs
  • Exhibit 11: Pipeline portfolio: Global CLL therapeutics market
  • Exhibit 12: Percentage share of drug candidates by stage of development 2015
  • Exhibit 13: Global CLL therapeutics market 2015-2020 ($ billions)
  • Exhibit 14: Total addressable market for global CLL therapeutics market 2015-2020 ($ billions)
  • Exhibit 15: Five forces analysis
  • Exhibit 16: Segmentation of global CLL therapeutics market by ROA 2015
  • Exhibit 17: Segmentation of global CLL therapeutics market by type of molecule 2015
  • Exhibit 18: Segmentation of global CLL therapeutics market based on geography 2015
  • Exhibit 19: Segmentation of global CLL therapeutics market based on geography 2020
  • Exhibit 20: Global CLL therapeutics market by geography 2015-2020 ($ millions)
  • Exhibit 21: Global CLL therapeutics market by geography 2015-2020
  • Exhibit 22: CLL therapeutics market in Americas 2015-2020 ($ billions)
  • Exhibit 23: CLL therapeutics market in EMEA 2015-2020 ($ billions)
  • Exhibit 24: CLL therapeutics market in APAC 2015-2020 ($ millions)
  • Exhibit 25: Global CLL therapeutics market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 26: Population aged 60 years and over: World, developed, and developing regions (millions)
  • Exhibit 27: Impact of drivers
  • Exhibit 28: Cost of therapy for CLL
  • Exhibit 29: Impact of drivers and challenges
  • Exhibit 30: SWOT: MabThera
  • Exhibit 31: SWOT: Imbruvica
  • Exhibit 32: SWOT: Treanda
  • Exhibit 33: SWOT of Zydelig
  • Exhibit 34: F. Hoffmann-La Roche: YoY growth and revenue generated from total product sales of MabThera/Rituxan (oncology indication) 2013-2015 ($ billions)
  • Exhibit 35: MabThera/Rituxan geographic segmentation by revenue 2015
  • Exhibit 36: F. Hoffmann-La Roche: Key takeaways
  • Exhibit 37: AbbVie: Key takeaways
  • Exhibit 38: Teva Pharmaceuticals: YoY revenue and growth rate of Treanda 2013-2015 ($ millions)
  • Exhibit 39: Teva Pharmaceuticals: Key takeaways
  • Exhibit 40: Johnson & Johnson: YoY revenue comparison of Imbruvica (Global) 2013-2015 ($ millions)
  • Exhibit 41: Johnson & Johnson: YoY revenue comparison of Imbruvica (US) 2013-2015 ($ millions)
  • Exhibit 42: Johnson & Johnson: YoY revenue comparison of Imbruvica (ROW) 2013-2015 ($ millions)
  • Exhibit 43: Johnson & Johnson: Geographic segmentation of Imbruvica 2015
  • Exhibit 44: Johnson & Johnson: Key takeaways
  • Exhibit 45: Gilead Sciences: YoY revenue and growth rate of Zydelig 2013-2015 ($ millions)
  • Exhibit 46: Gilead Sciences: Key takeaways
  • Exhibit 47: Novartis: Key takeaways
Back to Top